Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03222609 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
A Phase 2 study of Myelofibrosis (MF), sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 191
- Enrollment target
- 20
- Study locations
NCT03222609: Completed Phase 2 study of Myelofibrosis (MF), sponsored by AbbVie.
NCT03222609 is a Phase 2 study of Myelofibrosis (MF) that has completed, run by AbbVie. The registered enrollment target is 191 participants, below the 954-participant average among 6 other Myelofibrosis (MF) trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03222609, a Phase 2 study of Myelofibrosis (MF), has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 191 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
Primary Outcome
Reduction in spleen volume is measured by magnetic resonance imaging/computerized tomography (MRI/CT).
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Navitoclax
Study Locations (20)
California
- TOI Clinical Research /ID# 222546 - Cerritos
- City of Hope /ID# 221395 - Duarte
- Moores Cancer Center at UC San Diego /ID# 164084 - La Jolla
- Long Beach Memorial Medical Ct /ID# 230148 - Long Beach
- University of Southern California /ID# 164095 - Los Angeles
Florida
- Baptist MD Anderson Cancer Center - Jacksonville /ID# 222548 - Jacksonville
- Mayo Clinic /ID# 164201 - Jacksonville
- Moffitt Cancer Center /ID# 164082 - Tampa
Illinois
- University of Chicago Medicine /ID# 164115 - Chicago
- Mid Illinois Hematology & Oncology Associates, Ltd /ID# 230536 - Normal
Massachusetts
- Dana-Farber Cancer Institute /ID# 162675 - Boston
- University of Massachusetts - Worcester /ID# 222547 - Worcester
Michigan
- Henry Ford Hospital /ID# 162682 - Detroit
- Ascension Providence Southfield Cancer Center /ID# 223876 - Southfield
Alabama
- UAB Comprehensive Cancer Cente /ID# 165464 - Birmingham
Colorado
- Colorado Blood Cancer Institute /ID# 224250 - Denver
Indiana
- Indiana Blood & Marrow Transpl /ID# 165075 - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2025-01-29 |
| Phase | Phase 2 |
What the finished NCT03222609 record still lists
NCT03222609 is an interventional study that assigns participants to a tested intervention. The registered 191 participants enrollment target is mid-sized for trials with a published cap, below the 954-participant average among 6 other Myelofibrosis (MF) trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Myelofibrosis (MF) appearing as the primary indexed condition, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT03222609 names 20 study sites across 11 states, led by California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03222609 about?
NCT03222609 is a clinical study titled "A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis". This is a Phase 2 open-label, multicenter study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.
What is the current status of trial NCT03222609?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 191 participants. The study started on 2017-10-31. Estimated completion is 2025-01-29.
What conditions does trial NCT03222609 study?
This clinical trial studies the following conditions: Myelofibrosis (MF).
What interventions are being tested in trial NCT03222609?
The interventions under investigation include: Ruxolitinib (DRUG), Navitoclax (DRUG).
Who is sponsoring clinical trial NCT03222609?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03222609 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis (MF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
RECRUITING · Phase 2
-
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
RECRUITING · Phase 1
-
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
RECRUITING
-
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis
ACTIVE NOT RECRUITING · Phase 1
-
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
ACTIVE NOT RECRUITING · Phase 3
-
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04621435 · 191 participants · Phase 1
Imaging of Solid Tumors Using FAP-2286
- NCT06810544 · 191 participants · Phase 1
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI